1[1]Dudley E, Lemiere F, Van Dongen W, et al. Urinary modified nucleosides as tumor markers [J]. Nucleosides Nucleotides Nucleic Acids, 2003,22(5-8):987-989.
2[2]Zheng YF, Xu GW, Liu DY, et al. Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography [J]. Electrophoresis, 2002,23(24):4104-4109.
3[3]Limbach PA, Crain PF, McCloskey JA. Summary: the modified nucleosides of RNA [J]. Nucleic Acids Res,1994,22( 12):2183 -2196.
4[4]Bjork GR, Ericson JU, Gustafsson CE, et al. Transfer RNA modification [J]. Annu Rev Biochem, 1987,56(2):263-287.
5[5]Gehrke CW, Kuo KC, Waalkes TP, et al. Patterns of urinary excretion of modified nucleosides [J]. Cancer Res,1979,39(4): 1150-1153.
6[6]Rasmuson T, Bjork GR. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma [J]. Acta Oncol, 1995,34(1):61-67.
7[7]Waalkes TP, Adamson RH, O'Gara RW, et al. Transfer RNA methylase activity in normal monkey liver and in carcinogen-induced hepatoma[J]. Cancer Res, 1971,31(8):1069-1073.
8[8]Randerath K, Tseng WC, Harris JS, et al. Recent results in cancer research modified nucleosides and cancer[M].Berlin: Springer-Verlarg. 1983. 283.
9[9]Itoh K, Konno T, Sasaki T, et al. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma[J]. Clin Chim Acta, 1992,206(3):181-189.
10[10]Xu G, Schmid HR, Lu X, et al. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method[J]. Biomed Chromatogr, 2000,14(7):459-463.
4Liebich HM, Lehmann R, Xu G, et al.Application of capillary electrophoresis in clinical chemistry: the clinical value of urinary modified nucleosides. J Chromatogr B,2000,745:189-196.
5Liebich HM, Di Stefano C, Wixforth A, et al. Quantitation of urinary nucleosides by high-performance liquid chromatography. J Chromatogr A, 1997,763:193-197.
6Xu G, Schmid HR, Lu X, et al. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed Chromatogr, 2000,14:459-463.
7Zheng YF, Xu GW, Liu DY, et al. Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography. Electrophoresis, 2002,23:4104-4109.
8Zhao R, Xu G, Yue B, et al. Artificial neural network classification based on capillary electrophoresis of urinary nucleosides for the clinical diagnosis of tumors. J Chromatogr A,1998,828:489-496.
9Sasco AJ, Rey F, Reynaud C, et al. Breast cancer prognostic significance of some modified urinary nucleosides. Cancer Lett,1996,108:157-162.
5Nicholson JK,Lindon JC,Holmes E.'Metabonomics':Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J].Xenobiotica,1999,29:1181-1189.
6Nicholson JK,Wilson ID.Understanding 'global' systems biology:metabonomics and the continuum of metabolism[J].Nat Rev Drug Discov,2003,2:668-676.
7Oresic M,Viadal PA,Hanninen V.Metabolomic approaches to phenotype characterization and applications to complex diseases[J].Expert Rev Mol Diagn,2006,6(4):575-585.
8Mally A,Amberg A,Hard GC,et al.Are 4-hydroxy-2(E)-nonenal derived mercapturic acids and H-1 NMR metabonomics potential biomarkers of chemically induced oxidative stress in the kidney[J] ? Toxicology,2007,230(2-3):244-255.
